University of Adelaide is fighting antibiotic-resistant superbugs by starving them of iron

pharmafile | March 6, 2018 | News story | Manufacturing and Production, Research and Development Adelaide, Australia, Superbugs, antibiotic resistance, pharma 

A team of researchers from Australia’s University of Adelaide have developed a new method to fighting antibiotic-resistant bacteria by starving it of iron, the fuel it needs grow and threaten human health.

Antibiotic-resistant superbugs are a major cause for concern in the scientific and healthcare communities, presenting a threat that proves impervious to current attempts to fight them. They are responsible for around 700,000 deaths a year worldwide and the World Health Organization forecasts that this number will rise to 10 million by 2050 if suitable interventions are not found.

Researcher Dr Katharina Richter (pictured) explained: “Iron is like chocolate for bacteria. It gives them energy to grow, cause disease, and withstand attacks from our immune systems and antibiotics. Using two different compounds, we first starve the bacteria of iron and then feed them the bacterial equivalent of poisonous chocolate, which the hungry bacteria find irresistible.”

“This ‘double whammy’ approach has defeated superbugs like golden staph in laboratory and animal studies,” she added. “The treatment is locally applied at the infection site, precisely where it is needed without interfering with the entire body.”

Dr Richter notes that bacteria are unlikely to become resistant to their main fuel source, so the risk for developing resistance is low. The therapy is currently being trialled at Adelaide’s The Queen Elizabeth Hospital as a treatment for antibiotic-resistant sinus infections. The team is now in the process of recruiting patients with chronic recurring sinus infections to trial the therapy in the hopes of expanding its applications to fight other superbugs.

Matt Fellows

Related Content

FDA approves IMIDEX’s AI-powered device VisiRad XR

The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …

Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo

On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …


Novartis acquires Chinook Therapeutics for $3.5bn

Swiss pharmaceutical company Novartis has entered into an agreement and plan of merger with US-based …

Latest content